FDA Approves Lilly's Inluriyo–Verzenio Combination for ESR1-Mutated Breast Cancer
On September 18, 2026, the U.S. FDA granted full approval to Eli Lilly’s Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy. Lilly said the approval was based on the Phase 3 EMBER-3 trial, in which the combination doubled median progression-free survival versus Inluriyo alone in ESR1-mutated metastatic breast cancer.
The supplied wire and corroborating context identify a new, product-specific FDA approval: Eli Lilly’s Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after progression on at least one line of endocrine therapy. This is a forward-looking regulatory milestone with commercial and competitive implications, so it is retained as a regulatory_approval and approved for downstream use. The reported doubling of median progression-free survival supports a high importance score, while surprise is moderated because the input does not provide market expectations or consensus. Only September 18, 2026 is explicitly established as the approval date; the Telegram timestamp is treated as publication time rather than occurrence time, so 00:00Z is used as a date-only estimate with low timestamp precision. Eli Lilly is the direct stakeholder; Guardant Health and the named competing oral-SERD developers have plausible indirect exposure supported by the supplied diagnostic and competitive-market context.
LILLY'S COMBO DOUBLES PFS VS INLURIYO ALONE IN ESR1+ MBC || LILLY'S INLURIYO GETS SECOND FDA OK IN UNDER A YEAR